Navigation Links
Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Men's Rogaine® Foam
Date:5/2/2011

ALLEGAN, Mich., May 2, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Minoxidil Foam, a generic version of Men's Rogaine® Foam.

Perrigo had been sued for patent infringement by Stiefel Research Australia Pty. Ltd., a GSK Company, when it submitted its Paragraph IV ANDA.  Under the terms of the settlement reached between the parties in February 2011, Perrigo can launch the generic version of Men's Rogaine® Foam in the U.S. on March 1, 2012, or earlier, under certain circumstances. The product will be entitled to 180 days of generic exclusivity upon launch.

Rogaine® (Minoxidil) Foam is used to regrow hair on the top of the scalp, and has annual sales of approximately $60 million, as measured by Information Resources, Inc.  

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This is another example of Perrigo's commitment to bring new products to market. Perrigo continues to deliver on its mission to provide quality, affordable healthcare to consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.  The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 , First quarter 2016 ... of $964 million , First quarter reported ... , Company revises 2016 financial guidance; now ... billion and 2016 adjusted diluted non-GAAP earnings per share to ... provides updates regarding Generics business and manufacturing facility restructuring ...
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocythemia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocythemia Market and ... comprehensive insights into Thrombocythemia pipeline products, ...
(Date:5/4/2016)... 4, 2016 According to a ... Computer Interface Market - Global Industry Analysis, Size, Share, ... computer interface (BCI) market  is expected to reach a ... estimated to expand at a CAGR of 14.9 % ... A BCI device provides collaboration between the brain ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... A recent survey by the Midwest Business Group ... to understand and use the free preventive care benefits available to them as part ... of large, self-insured public and private employers, MBGH found that only 10% of large ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... provide focused resources for veterinary professionals across the United States. The whole food ... lives of their patients and giving dog, cat and horse owners’ peace of ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
(Date:5/5/2016)... MA (PRWEB) , ... May 05, 2016 , ... Chronic ... becomes a constant presence, it can weaken the immune system and increase inflammation, both ... B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts General ...
(Date:5/5/2016)... ... ... With May flowers, summer is just around the corner. Summer means a lot of different ... the ability to play all day and night. Parents often lament the coming of summer ... themselves. Summer also means trips to the beach, backyard cookouts, fireworks on the Fourth of ...
Breaking Medicine News(10 mins):